Sign Up to like & get
recommendations!
1
Published in 2022 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2022.972411
Abstract: Pyrotinib, a novel irreversible epidermal growth factor receptor dual tyrosine kinase inhibitor, is mainly (about 90%) eliminated through cytochrome P450 (CYP) 3A mediated metabolism in vivo. Meanwhile, genotype is a key factor affecting pyrotinib clearance…
read more here.
Keywords:
pyrotinib exposure;
endogenous biomarker;
model;
pyrotinib ... See more keywords